Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Lang

Showing results (291-300 of 312) with videos related to

Pageof 32
Sort By:
Haematologica|February 13, 2016
Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemiaSandra Preuner, Christina Peters, Ulrike Pötschger, et al.
American Journal of Hematology|June 8, 2026
Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-ThalassemiaSujit Sheth, Selim Corbacioglu, Josu de la Fuente, et al.
Leukemia|September 13, 2022
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trialAnna Eichinger, Ulrike Poetschger, Evgenia Glogova, et al.
Leukemia|December 7, 2019
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trialAndishe Attarbaschi, Georg Mann, Martin Zimmermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2023
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II TrialTim Flaadt, Ruth L Ladenstein, Martin Ebinger, et al.
The New England Journal of Medicine|April 24, 2024
Exagamglogene Autotemcel for Transfusion-Dependent β-ThalassemiaFranco Locatelli, Peter Lang, Donna Wall, et al.
European Journal of Human Genetics : EJHG|July 28, 2023
Clinical trio genome sequencing facilitates the interpretation of variants in cancer predisposition genes in paediatric tumour patientsChristopher Schroeder, Ulrike Faust, Luisa Krauße, et al.
Nature Communications|July 4, 2023
Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCNSteffen Fuchs, Clara Danßmann, Filippos Klironomos, et al.
Oncoimmunology|June 10, 2022
Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targetingChristian M Seitz, Joerg Mittelstaet, Daniel Atar, et al.
Bone Marrow Transplantation|May 16, 2019
Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALLFlorian Babor, Christina Peters, Angela R Manser, et al.
Pageof 32

Showing results (291-300 of 312) with videos related to

Sort By:
Pageof 32
Haematologica|February 13, 2016
Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemiaSandra Preuner, Christina Peters, Ulrike Pötschger, et al.
American Journal of Hematology|June 8, 2026
Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-ThalassemiaSujit Sheth, Selim Corbacioglu, Josu de la Fuente, et al.
Leukemia|September 13, 2022
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trialAnna Eichinger, Ulrike Poetschger, Evgenia Glogova, et al.
Leukemia|December 7, 2019
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trialAndishe Attarbaschi, Georg Mann, Martin Zimmermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2023
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II TrialTim Flaadt, Ruth L Ladenstein, Martin Ebinger, et al.
The New England Journal of Medicine|April 24, 2024
Exagamglogene Autotemcel for Transfusion-Dependent β-ThalassemiaFranco Locatelli, Peter Lang, Donna Wall, et al.
European Journal of Human Genetics : EJHG|July 28, 2023
Clinical trio genome sequencing facilitates the interpretation of variants in cancer predisposition genes in paediatric tumour patientsChristopher Schroeder, Ulrike Faust, Luisa Krauße, et al.
Nature Communications|July 4, 2023
Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCNSteffen Fuchs, Clara Danßmann, Filippos Klironomos, et al.
Oncoimmunology|June 10, 2022
Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targetingChristian M Seitz, Joerg Mittelstaet, Daniel Atar, et al.
Bone Marrow Transplantation|May 16, 2019
Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALLFlorian Babor, Christina Peters, Angela R Manser, et al.
Pageof 32